<DOC>
	<DOCNO>NCT01319864</DOCNO>
	<brief_summary>In Phase I study , test safety drug plerixafor ( MOBOZIL ) different dose level , use together anti-cancer drugs—cytarabine etoposide . We want find effect , good /or bad , combination drug leukemia . Plerixafor drug block receptor leukemia cell , prevents stay bone marrow resistant chemotherapy . Plerixafor FDA approve mobilize stem cell bone marrow preparation autologous stem cell transplant . Cytarabine etoposide use part standard chemotherapy ALL AML . However , use plerixafor cytarabine etoposide pediatric patient relapse refractory ALL , AML MDS consider experimental .</brief_summary>
	<brief_title>POETIC Plerixafor Chemosensitizing Agent Relapsed Acute Leukemia MDS Pediatric Patients</brief_title>
	<detailed_description>Approximately 500 child diagnose AML every year , around 60 % cured current regimen base anthracyclines high dose cytarabine without stem cell transplant ( SCT ) . Among remain 40 % refractory relapse , outcome dismal . Additionally , 20-30 % patient childhood ALL relapse become refractory frontline therapy . The prognosis poor patient population , particularly patient second subsequent relapse relapse follow SCT . These patient present myriad challenge , usually receive high cumulative anthracycline dose , case SCT , may significant organ toxicity and/or total body irradiation ( TBI ) . Therefore , new therapeutic strategy need identify enhance possible improve outcome . Recently , scientist describe resistant , quiescent population leukemia cell limitless self-renewal potential . The identification `` leukemia stem cell '' ( LSCs ) provide additional strategy treat prevent relapsed/refractory acute leukemia . One mechanism resistance treatment protection afford LSCs via interaction stem cell derive growth factor ( CXCL-12/SDF-1α ) receptor , CXCR4 . These interaction implicate chemotaxis , homing , survival/apoptosis hematopoietic stem cell progenitor cell . All AML ALL cell express CXCR4 SDF-1α . AMD3100 ( plerixafor , MOBOZIL® ) bicyclam block CXCL-12 bind signal CXCR4 , thus disrupt tumor-stroma interaction mobilize leukemia cell protective stromal environment . Plerixafor currently FDA approve use stem cell mobilization autologous transplantation hematologic malignancy . Clinical trial adult patient relapse AML demonstrate promising result combine plerixafor cytotoxic chemotherapy . This Phase I clinical trial first test concept `` chemosensitization '' approach child use Plerixafor . Patients age 3 30 relapsed/refractory AML , ALL MDS receive Plerixafor follow 4 hour later combination chemotherapy consist etoposide cytarabine daily five day . We determine safety tolerability Plerixafor combination cytarabine etoposide pediatric young adult relapsed/refractory acute leukemia . The secondary objective study quantify peripheral blood mobilization blast response Plerixafor use flow cytometry , measure initial CXCR4 expression leukemic blast correlate response , determine change CXCR4 expression protocol therapy . Finally , determine pharmacokinetics Plerixafor administer cytotoxic chemotherapy patient population .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>&gt; = 3 year age &lt; 30 year old study entry diagnosis relapsed/refractory AML , ALL , secondary AML/MDS , acute leukemia ambiguous lineage meet follow criterion : AML/MDS leukemia ambiguous lineage must &gt; 5 % blast bone marrow ALL must M3 marrow ALL AML must CNS disease patient must fully recover acute toxic effect prior chemotherapy , immunotherapy radiotherapy prior enter study Karnofsky score &gt; 50 % patient &gt; 16 year age Lansky &gt; 50 % patient &lt; = 16 year age adequate renal hepatic function define protocol adequate cardiac function define protocol ALL AML patient CNS disease Absolute blast count great 50,000/mcl Systemic fungal , bacterial , viral infection without improvement despite appropriate antibiotic treatment Significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance Patients second cancer , include secondary AML Patients pregnant</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>leukemia</keyword>
</DOC>